331 related articles for article (PubMed ID: 23308186)
21. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
[TBL] [Abstract][Full Text] [Related]
22. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
24. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.
Lin X; Tench CR; Turner B; Blumhardt LD; Constantinescu CS
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1090-4. PubMed ID: 12876240
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
[TBL] [Abstract][Full Text] [Related]
26. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
27. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
28. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
29. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
31. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
33. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
35. Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Chang I; Kappos L; Giovannoni G; Calabresi PA; Sandrock A; Cheng W; Xiao S; Riester K; Belachew S; Deykin A; Zhu B
Mult Scler; 2022 Dec; 28(14):2263-2273. PubMed ID: 36131595
[TBL] [Abstract][Full Text] [Related]
36. Is natalizumab a breakthrough in the treatment of multiple sclerosis?
Doggrell SA
Expert Opin Pharmacother; 2003 Jun; 4(6):999-1001. PubMed ID: 12783595
[TBL] [Abstract][Full Text] [Related]
37. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
39. Interferon beta for secondary progressive multiple sclerosis.
La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
[TBL] [Abstract][Full Text] [Related]
40. History of modern multiple sclerosis therapy.
Lublin F
J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]